IDH-mutant gliomas convert isocitrate into 2-hydroxyglutarate, which competitively inhibits α-KG-dependent DNA and histone demethylases, contributing to the downregulation of BCAT1/2 function through DNA methylation of its promoter [154]. The gene discussed is BCAT1; the disease is central nervous system cancer.